vs

Side-by-side financial comparison of Teradyne (TER) and Zimmer Biomet (ZBH). Click either name above to swap in a different company.

Zimmer Biomet is the larger business by last-quarter revenue ($2.1B vs $1.3B, roughly 1.6× Teradyne). Teradyne runs the higher net margin — 31.1% vs 11.4%, a 19.7% gap on every dollar of revenue. On growth, Teradyne posted the faster year-over-year revenue change (87.0% vs 9.3%). Over the past eight quarters, Teradyne's revenue compounded faster (32.6% CAGR vs 3.7%).

Teradyne, Inc. is an American automatic test equipment (ATE) designer and manufacturer based in North Reading, Massachusetts. Its high-profile customers include Samsung, Qualcomm, Intel, Analog Devices, Texas Instruments and IBM.

Zimmer Biomet Holdings, Inc. is a publicly traded American medical device company. It was founded in 1927 to produce aluminum splints. The firm is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster.

TER vs ZBH — Head-to-Head

Bigger by revenue
ZBH
ZBH
1.6× larger
ZBH
$2.1B
$1.3B
TER
Growing faster (revenue YoY)
TER
TER
+77.7% gap
TER
87.0%
9.3%
ZBH
Higher net margin
TER
TER
19.7% more per $
TER
31.1%
11.4%
ZBH
Faster 2-yr revenue CAGR
TER
TER
Annualised
TER
32.6%
3.7%
ZBH

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
TER
TER
ZBH
ZBH
Revenue
$1.3B
$2.1B
Net Profit
$398.9M
$238.3M
Gross Margin
60.9%
64.6%
Operating Margin
36.9%
17.9%
Net Margin
31.1%
11.4%
Revenue YoY
87.0%
9.3%
Net Profit YoY
30.5%
EPS (diluted)
$2.53
$1.22

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
TER
TER
ZBH
ZBH
Q1 26
$1.3B
$2.1B
Q4 25
$1.1B
$2.2B
Q3 25
$769.2M
$2.0B
Q2 25
$651.8M
$2.1B
Q1 25
$685.7M
$1.9B
Q4 24
$752.9M
$2.0B
Q3 24
$737.3M
$1.8B
Q2 24
$729.9M
$1.9B
Net Profit
TER
TER
ZBH
ZBH
Q1 26
$398.9M
$238.3M
Q4 25
$257.2M
$139.4M
Q3 25
$119.6M
$230.9M
Q2 25
$78.4M
$152.8M
Q1 25
$98.9M
$182.0M
Q4 24
$146.3M
$239.5M
Q3 24
$145.6M
$249.1M
Q2 24
$186.3M
$242.8M
Gross Margin
TER
TER
ZBH
ZBH
Q1 26
60.9%
64.6%
Q4 25
57.2%
64.7%
Q3 25
58.4%
72.1%
Q2 25
57.2%
71.5%
Q1 25
60.6%
71.2%
Q4 24
59.4%
71.0%
Q3 24
59.2%
70.5%
Q2 24
58.3%
71.5%
Operating Margin
TER
TER
ZBH
ZBH
Q1 26
36.9%
17.9%
Q4 25
27.1%
6.9%
Q3 25
18.9%
17.6%
Q2 25
13.9%
14.4%
Q1 25
17.6%
15.3%
Q4 24
20.4%
19.2%
Q3 24
20.6%
15.3%
Q2 24
28.8%
18.1%
Net Margin
TER
TER
ZBH
ZBH
Q1 26
31.1%
11.4%
Q4 25
23.7%
6.2%
Q3 25
15.5%
11.5%
Q2 25
12.0%
7.4%
Q1 25
14.4%
9.5%
Q4 24
19.4%
11.8%
Q3 24
19.8%
13.7%
Q2 24
25.5%
12.5%
EPS (diluted)
TER
TER
ZBH
ZBH
Q1 26
$2.53
$1.22
Q4 25
$1.62
$0.71
Q3 25
$0.75
$1.16
Q2 25
$0.49
$0.77
Q1 25
$0.61
$0.91
Q4 24
$0.89
$1.18
Q3 24
$0.89
$1.23
Q2 24
$1.14
$1.18

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
TER
TER
ZBH
ZBH
Cash + ST InvestmentsLiquidity on hand
$241.9M
$424.2M
Total DebtLower is stronger
$0
$7.5B
Stockholders' EquityBook value
$12.7B
Total Assets
$4.4B
$22.7B
Debt / EquityLower = less leverage
0.59×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
TER
TER
ZBH
ZBH
Q1 26
$241.9M
$424.2M
Q4 25
$293.8M
$591.9M
Q3 25
$272.7M
$1.3B
Q2 25
$339.3M
$556.9M
Q1 25
$475.6M
$1.4B
Q4 24
$553.4M
$525.5M
Q3 24
$510.0M
$569.0M
Q2 24
$421.9M
$420.1M
Total Debt
TER
TER
ZBH
ZBH
Q1 26
$0
$7.5B
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
TER
TER
ZBH
ZBH
Q1 26
$12.7B
Q4 25
$2.8B
$12.7B
Q3 25
$2.7B
$12.8B
Q2 25
$2.8B
$12.5B
Q1 25
$2.8B
$12.4B
Q4 24
$2.8B
$12.5B
Q3 24
$2.9B
$12.4B
Q2 24
$2.7B
$12.7B
Total Assets
TER
TER
ZBH
ZBH
Q1 26
$4.4B
$22.7B
Q4 25
$4.2B
$23.1B
Q3 25
$4.0B
$23.5B
Q2 25
$3.8B
$22.9B
Q1 25
$3.7B
$22.2B
Q4 24
$3.7B
$21.4B
Q3 24
$3.8B
$21.7B
Q2 24
$3.6B
$21.5B
Debt / Equity
TER
TER
ZBH
ZBH
Q1 26
0.59×
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
TER
TER
ZBH
ZBH
Operating Cash FlowLast quarter
$265.1M
$359.4M
Free Cash FlowOCF − Capex
$245.9M
FCF MarginFCF / Revenue
11.8%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
0.66×
1.51×
TTM Free Cash FlowTrailing 4 quarters
$1.4B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
TER
TER
ZBH
ZBH
Q1 26
$265.1M
$359.4M
Q4 25
$281.6M
$517.4M
Q3 25
$49.0M
$418.7M
Q2 25
$182.1M
$378.2M
Q1 25
$161.6M
$382.8M
Q4 24
$282.6M
$506.3M
Q3 24
$166.3M
$395.7M
Q2 24
$216.1M
$369.4M
Free Cash Flow
TER
TER
ZBH
ZBH
Q1 26
$245.9M
Q4 25
$218.8M
$442.6M
Q3 25
$2.4M
$363.7M
Q2 25
$131.7M
$328.1M
Q1 25
$97.6M
$338.2M
Q4 24
$225.2M
$454.8M
Q3 24
$114.4M
$351.2M
Q2 24
$171.2M
$316.7M
FCF Margin
TER
TER
ZBH
ZBH
Q1 26
11.8%
Q4 25
20.2%
19.7%
Q3 25
0.3%
18.2%
Q2 25
20.2%
15.8%
Q1 25
14.2%
17.7%
Q4 24
29.9%
22.5%
Q3 24
15.5%
19.3%
Q2 24
23.5%
16.3%
Capex Intensity
TER
TER
ZBH
ZBH
Q1 26
Q4 25
5.8%
3.3%
Q3 25
6.1%
2.7%
Q2 25
7.7%
2.4%
Q1 25
9.3%
2.3%
Q4 24
7.6%
2.5%
Q3 24
7.0%
2.4%
Q2 24
6.1%
2.7%
Cash Conversion
TER
TER
ZBH
ZBH
Q1 26
0.66×
1.51×
Q4 25
1.09×
3.71×
Q3 25
0.41×
1.81×
Q2 25
2.32×
2.48×
Q1 25
1.63×
2.10×
Q4 24
1.93×
2.11×
Q3 24
1.14×
1.59×
Q2 24
1.16×
1.52×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons